Galectin Therapeutics Inc. (NASDAQ: GALT) filed a Current Report on Form 8-K on November 16, 2026, announcing its financial results for the three months ended September 30, 2026, and providing a business update. The company reported a net loss applicable to common stockholders of $3.6 million, or ($0.04) per share, for the quarter, compared to a net loss of $8.2 million, or ($0.13) per share, in the same period of the prior year.

Research and development expenses for the quarter were $1.6 million, a decrease from $2.6 million in the prior year, primarily due to timing of expenditures related to the NAVIGATE clinical trial. General and administrative expenses increased to $1.8 million from $1.6 million, attributed to an increase in non-cash, stock-based compensation expense.

As of September 30, 2026, the company held $11.7 million in cash and cash equivalents. Additionally, it has $10 million remaining available under a line of credit provided by Chairman of the Board Richard E. Uihlein. The company stated it believes it has sufficient cash to fund operations and research and development through June 2027.

A significant corporate development occurred in the third quarter regarding the company's capital structure. Chairman of the Board and largest stockholder Richard E. Uihlein converted all outstanding principal and accrued interest under five of the company’s line of credit facilities into common stock, effective July 31, 2026. This transaction eliminated approximately $105.8 million in total debt, consisting of $91.0 million in principal and $14.8 million in accrued interest, and resulted in the issuance of 34,376,167 shares of common stock to Mr. Uihlein.

On the clinical front, Galectin submitted its registrational Phase 3 protocol for belapectin in advanced MASH cirrhosis with portal hypertension to the FDA in the third quarter. The company reached alignment with the FDA on key elements of the trial design, including the primary endpoint of a composite liver outcome and the use of a single, 2 mg/kg dose based on lean body mass.

At the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver, the company presented new analyses from its NAVIGATE Phase 2b/3 trial. An oral presentation highlighted that belapectin treatment was associated with a net 15.9% placebo-adjusted improvement in predicted clinically significant portal hypertension risk at 18 months (p=0.04). The company also presented posters regarding risk stratification using Baveno VII criteria and the ELF score.